Abstract
Chronic cavitary pulmonary aspergillosis (CCPA) has been associated with advanced lung diseases. Pulmonary sarcoidosis, a granulomatous inflammatory disorder, is associated with CCPA. We identified CCPA in 2% of cases in a large cohort of sarcoidosis patients. We found a lack of response to medical treatment and poor outcome in this subgroup.
Publication types
-
Case Reports
-
Research Support, Non-U.S. Gov't
-
Review
MeSH terms
-
Adult
-
Aged
-
Antifungal Agents / therapeutic use
-
Female
-
Humans
-
Itraconazole / therapeutic use
-
Male
-
Middle Aged
-
Pulmonary Aspergillosis / drug therapy
-
Pulmonary Aspergillosis / epidemiology*
-
Pyrimidines / therapeutic use
-
Risk Factors
-
Sarcoidosis, Pulmonary / complications*
-
Treatment Outcome
-
Triazoles / therapeutic use
-
Voriconazole
Substances
-
Antifungal Agents
-
Pyrimidines
-
Triazoles
-
Itraconazole
-
Voriconazole